EPY 201
Alternative Names: AAV9-CAMK2A-EKC; EPY-201Latest Information Update: 19 Jul 2024
At a glance
- Originator EpilepsyGTx
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Kv1.1 potassium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Epilepsy
Most Recent Events
- 24 Jun 2024 Preclinical trials in Epilepsy in United Kingdom (Intracerebral) before June 2024
- 24 Jun 2024 Pharmacodynamics and adverse events data from a preclinical trial in Epilepsy released by EpilepsyGTx (EpilepsyGTx pipeline, June 2024)
- 24 Jun 2024 EpilepsyGTx plans a phase I/IIa trial for Epilepsy (Intracerebral) (EpilepsyGTx pipeline, June 2024)